Filters

Pp-192 manufacturers

Filters

None products found

pp-192

Solution for infusion

Dossier type
EU CTD
Dossier status
Under development
Country of origin
European Union
GMP approvals
EU GMP
Comments
Indication: Solid tumours — uterine carcinosarcoma/sarcoma; multiple solid tumour types Clinical stage: Phase 2 Modality: Biological (first-in-class anti-Netrin-1 humanised monoclonal antibody) Mechanism / Target: Blocks Netrin-1 guidance protein that activates pro-survival signalling in cancer cells (via DCC/UNC5 dependence receptors); releases Netrin-1-driven inhibition of apoptosis in tumour cells and restores anti-tumour immune surveillance Route / form: IV infusion Differentiation: First-in-class anti-Netrin-1 mAb; novel pro-apoptotic mechanism targeting a cancer survival signal distinct from VEGF or checkpoint pathways; promising signal in uterine sarcoma/carcinosarcoma — rare cancer with no approved second-line therapy;
Manufacturer #39332
Europe-based clinical-stage biotech developing Rx antibody therapies that target a resistance pathway to improve response to chemotherapy and immunotherapy. Lead program is advancing in clinical trials for solid tumors.

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Willing to unlock more features?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.